On the strength of a promising phase I clinical trial, evaluations are continuing for an experimental immunotherapy that targets and selectively kills melanoma cells. Called IMCgp100, the drug has two parts that are fused together. One part is an immune system protein that has been engineered to recognize a protein called gp100, which is on the surface of melanoma cells. The other part of the new drug is a protein fragment that boosts the immune response against the tumor. The phase II trial of IMCgp100 is currently recruiting new participants.